ArticleInternational urology and nephrology2026
Signet ring cell carcinoma of the urachus: survival and pathologic outcomes from the national cancer database.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Robotic Partial Cystectomy and Extended Pelvic Lymph Node Dissection for Node-Positive Urachal Adenocarcinoma in a 34-Year-Old Woman: A Case Report.Current oncology (Toronto, Ont.) · 2026Article
- Urachal Carcinoma with Divergent Glandular Enteric-Type and Squamous Differentiation Associated with Bladder Exstrophy: Case Report of an Extremely Rare Entity.Reports (MDPI) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSignet ring cell carcinoma (SRCC) of the urachus is a rare and aggressive histologic variant with limited guidance on optimal treatment. This study aimed to characterize the clinicopathological features, treatment patterns, and survival outcomes of urachal SRCC using a large national dataset and to assess the impact of surgical and systemic therapies on prognosis.
methodsWe queried the National Cancer Database (NCDB) for patients diagnosed with urachal SRCC between 2004 and 2020. Clinical and pathological staging, surgical approach (partial vs. radical cystectomy), chemotherapy use, and overall survival were analyzed. Kaplan-Meier survival curves and statistical comparisons were used to evaluate treatment outcomes.
resultsA total of 60 patients with SRCC of the urachus were identified. A substantial proportion presented with advanced or unstaged disease (43.3% cTX, 38.4% pTX). Partial cystectomy was performed more often than radical cystectomy (56.7% vs. 31.6%). Chemotherapy was administered in 38.4% of patients, most commonly as multi-agent regimens. Median overall survival was approximately 30 months. No significant survival benefit was observed with chemotherapy administration.
conclusionUrachal SRCC is associated with poor survival and considerable heterogeneity in staging and management. Our findings suggest limited observed benefit of systemic therapy in this cohort, underscoring the need for further prospective studies.
Indexed as
Identifiers
41231381What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.